{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:10:38Z","timestamp":1777590638697,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>To assess the feasibility and efficacy of delivering a radiation dose boost to high-risk glioblastoma (GBM) tumor regions, identified using magnetic resonance spectroscopy (MRS) after standard radiotherapy (RT). This retrospective study included patients newly diagnosed with GBM between January 2017 and July 2023. All patients received Intensity-modulated radiotherapy and concurrent temozolomide. Magnetic resonance imaging (MRI) and MRS were performed prior to radiotherapy and after the administration of 60Gy. A biological gross tumor volume (bGTV) was delineated on the simulation CT using the image fusion with the T1 sequence with MRS data after 60Gy. Based on the bGTV volume, patients received an additional 10-20Gy. Survival outcomes were estimated using Kaplan\u2013Meier methods, and Cox regression analysis was applied to explore associations between clinical factors and survival. A total of 114 patients were analyzed. The median patient age was 51 years (range: 18\u201378 years), and 60.5% were male. Gross total resection was performed in 76 patients prior to RT. IDH1\/2 wild-type was identified in 99 patients, and MGMT methylation was present in 40 patients. The median follow-up period was 34.0 months (95% CI, 27.1\u201340.9 months). The median overall survival (OS) and progression free survival (PFS) were 30.0 months (95%. CI 21.5\u201338.5 months), and 12.0 months (95%CI 9.5\u201314.5 months), respectively. Both univariate and multivariate analyses showed that the type of surgical resection and IDH1\/2 mutation status were significantly associated with OS and PFS. Headache and fatigue were the most frequently reported symptoms. Delivering a RT boost to high-risk tumor regions identified by MRS after standard RT is feasible in patients with GBM and demonstrate acceptable toxicity. Further prospective clinical trials are warranted to confirm these findings.<\/jats:p>","DOI":"10.1038\/s41598-025-87632-1","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T02:17:17Z","timestamp":1744942637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Magnetic resonance spectroscopy guided radiotherapy boost for patients with glioblastoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Peng","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia Clara","family":"Orlandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyi","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"87632_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"87632_CR2","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","volume":"24","author":"R-O Mirimanoff","year":"2006","unstructured":"Mirimanoff, R.-O. et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol. 24, 2563\u20132569 (2006).","journal-title":"J. Clin. Oncol."},{"key":"87632_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","volume":"60","author":"L Souhami","year":"2004","unstructured":"Souhami, L. et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of radiation therapy oncology group 93\u201305 protocol. Int. J. Radiat. Oncol. 60, 853\u2013860 (2004).","journal-title":"Int. J. Radiat. Oncol."},{"key":"87632_CR4","first-page":"823","volume":"49","author":"D Croteau","year":"2001","unstructured":"Croteau, D. et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: Semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery. 49, 823\u2013829 (2001).","journal-title":"Neurosurgery."},{"key":"87632_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0360-3016(01)01548-6","volume":"50","author":"A Pirzkall","year":"2001","unstructured":"Pirzkall, A. et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 50, 915\u2013928 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"87632_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijrobp.2012.01.020","volume":"84","author":"DB Einstein","year":"2012","unstructured":"Einstein, D. B. et al. Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 84, 668\u2013674 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"87632_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","volume":"118","author":"M Niyazi","year":"2016","unstructured":"Niyazi, M. et al. ESTRO-ACROP guideline \u201ctarget delineation of glioblastomas\u201d. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 118, 35\u201342 (2016).","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"87632_CR8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 318, 2306\u20132316 (2017).","journal-title":"JAMA."},{"key":"87632_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-023-04391-7","volume":"164","author":"S Mallick","year":"2023","unstructured":"Mallick, S. et al. Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: Updated results from phase II HART-GBM trial. J. Neurooncol. 164, 141\u2013146 (2023).","journal-title":"J. Neurooncol."},{"key":"87632_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11547-017-0806-y","volume":"123","author":"S Scoccianti","year":"2018","unstructured":"Scoccianti, S. et al. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiol. Med. (Torino) 123, 48\u201362 (2018).","journal-title":"Radiol. Med. (Torino)"},{"key":"87632_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1078-0432.CCR-11-2073","volume":"18","author":"CI Tsien","year":"2012","unstructured":"Tsien, C. I. et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18, 273\u2013279 (2012).","journal-title":"Off. J. Am. Assoc. Cancer Res."},{"key":"87632_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00066-011-0060-5","volume":"188","author":"MD Piroth","year":"2012","unstructured":"Piroth, M. D. et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al. 188, 334\u2013339 (2012).","journal-title":"Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al."},{"key":"87632_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2010.10.018","volume":"82","author":"AM Monjazeb","year":"2012","unstructured":"Monjazeb, A. M. et al. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 82, 743\u2013748 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"87632_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.ijrobp.2005.08.013","volume":"64","author":"JG Douglas","year":"2006","unstructured":"Douglas, J. G. et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 64, 886\u2013891 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"87632_CR15","doi-asserted-by":"publisher","first-page":"vdac006","DOI":"10.1093\/noajnl\/vdac006","volume":"4","author":"K Ramesh","year":"2022","unstructured":"Ramesh, K. et al. A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma. Neuro-Oncol. Adv. 4, vdac006 (2022).","journal-title":"Neuro-Oncol. Adv."},{"key":"87632_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijrobp.2021.05.001","volume":"111","author":"R Singh","year":"2021","unstructured":"Singh, R. et al. Dose escalated radiation therapy for glioblastoma multiforme: An international systematic review and meta-analysis of 22 prospective trials. Int. J. Radiat. Oncol. Biol. Phys. 111, 371\u2013384 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"87632_CR17","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ijrobp.2020.07.2109","volume":"108","author":"V Gondi","year":"2020","unstructured":"Gondi, V. et al. Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG oncology BN001. Int. J. Radiat. Oncol. 108, S22\u2013S23 (2020).","journal-title":"Int. J. Radiat. Oncol."},{"key":"87632_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/noad119","volume":"26","author":"A Laprie","year":"2024","unstructured":"Laprie, A. et al. Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial). Neuro-Oncol. 26, 153 (2024).","journal-title":"Neuro-Oncol."},{"key":"87632_CR19","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/j.clon.2024.04.011","volume":"36","author":"R Madan","year":"2024","unstructured":"Madan, R. et al. Prospective phase II study of radiotherapy dose escalation in grade 4 glioma using 68Ga-pentixafor PET scan. Clin. Oncol. R. Coll. Radiol. G. B. 36, e294\u2013e300 (2024).","journal-title":"Clin. Oncol. R. Coll. Radiol. G. B."},{"key":"87632_CR20","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1158\/1078-0432.CCR-22-0171","volume":"28","author":"M Harat","year":"2022","unstructured":"Harat, M. et al. Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma. Clin. Cancer Res Off. J. Am. Assoc. Cancer Res. 28, 3011\u20133020 (2022).","journal-title":"Clin. Cancer Res Off. J. Am. Assoc. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87632-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87632-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87632-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T02:17:17Z","timestamp":1744942637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87632-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87632"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87632-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13371"}}